Drugs / RJK-RT2831
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06756451 | Mar 2025 → Apr 2028 expected | hematopoietic and lymphoid cell neoplasm | Nanjing RegeneCore Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RJK-RT2831 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06756451 ↗ |
| Route | Intravenous | “by intravenous push or intravenous infusion” NCT06756451 ↗ |